Cayuga Biotech Press Releases

• Published on March 29, 2025 - 20:30 GMT

  Cayuga's CAY001 Significantly Increases Survival and Improves Bleeding Outcomes in Platelet Inhibitor-Related Bleeding

  Data on CAY001, a First-in-Class, Polyphosphate (polyP)-Based Therapy, Show Promise in Bypassing P2Y12 Inhibition to Restore Normal Clotting Function NEW YORK, NY, UNITED STATES, March 29, 2025 /⁨EINPresswire.com⁩/ -- Cayuga Biotech, a company that …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Military Industry ...
• Published on December 10, 2024 - 02:00 GMT

  Cayuga's poly-P-SNP Complex Demonstrates >90% Shorter Bleeding Time and Nearly 60% Less Blood Loss After Severe Injury

  -- Data on Novel Synthetic Short-Chain Polyphosphate (polyP) Complexed with Silica Nanoparticle (SNP) Presented at 66th ASH Annual Meeting -- NEW YORK, NY, UNITED STATES, December 9, 2024 /⁨EINPresswire.com⁩/ -- Cayuga Biotech, a company that develops …

  Distribution channels: Emergency Services, Healthcare & Pharmaceuticals Industry ...